Nephrology News

Health-related quality of life scores after kidney transplantation varied between patients who survived for at least 3 years and those who died during this time, leading researchers to suggest such tools may help identify at-risk patients.

The prevalence of obesity has increased for patients initiating peritoneal dialysis in China during the past 25 years, research published in the Clinical Kidney Journal revealed.

For patients receiving maintenance hemodialysis, infection with Staphylococcus aureus bacteremia led to worsening clinical outcomes, including increased in mortality, in a 21-year period.

A survey of patients scheduled for nephrology telemedicine visits at University of Pennsylvania-affiliated clinics revealed age and racial inequities in the likelihood of completing virtual visits.

Patients with childhood-onset lupus nephritis should receive up to three infusions of methylprednisolone at 30 mg/kg per dose upon diagnosis, with a maximum 60 mg of daily oral corticosteroids in the first 4 weeks, according to researchers.

Home dialysis with either partial or full assistance led to annual cost savings compared with dialysis administered in a hospital or center, an analysis evaluating the cost of maintenance care in Manitoba, Canada, showed.

An analysis of DAPA-CKD data showed dapagliflozin reduces the risk for kidney failure and mortality in patients with advanced chronic kidney disease, a subgroup that made up 14% of the study population included in the initial trial.

Results from the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems survey indicated that more frequent visits by nephrologists were not associated with improved patient-reported experiences.

For patients with cancer, the use of immune checkpoint inhibitors was associated with rapid eGFR decline and the subsequent development of chronic kidney disease 1 year after therapy initiation, study findings showed.

The SGLT2 inhibitor ertugliflozin shows promise for preserving kidney function in patients with type 2 diabetes and atherosclerotic cardiovascular disease, results of a placebo-controlled trial suggested.